Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

Tonix Pharmaceuticals Holding / Equity Bottom-Up

<ul><li>On April 1, 2024, Tonix Pharmaceuticals Holding Corp.</li><li>(TNXP) announced financial results for the fourth quarter and full year 2023 and provided a business update.</li><li>Tonix will be filing a New Drug Application (NDA) for TNX-102 SL (cyclobenzaprine HCl) for fibromyalgia in the second half of 2024 based on positive results from the Phase 3 RELIEF and RESILIENT trials.</li></ul>

On April 1, 2024, Tonix Pharmaceuticals Holding Corp.(TNXP) announced financial results for the fourth quarter and full year 2023 and provided a business update.Tonix will be filing a New Drug Application (NDA) for TNX-102 SL (cyclobenzaprine HCl) for fibromyalgia in the second half of 2024 based on positive results from the Phase 3 RELIEF and RESILIENT trials.

TNXP: Approval of First New Fibromyalgia Drug in 15 Years Possible in 2025 